A treatment for dry eye syndrome is to undergo a phase III randomized, placebo-controlled, multicentre study this year following a final licensing agreement with Celtic Therapeutics.
A treatment for dry eye syndrome is to undergo a phase III randomized, placebo-controlled, multicentre study this year following a final licensing agreement with Celtic Therapeutics.
Resolvyx Pharmacuticals' RX-10045 is a resolvin that will be administered as a topical eye drop. In a large Phase II placebo-controlled study it was found that the eye drop produced dose-dependent, improvement on the primary endpoints for both signs and symptoms of dry eye, and was shown to be safe and well-tolerated.
Resolvins have demonstrated high potency and efficacy in the treatment of dry eye and retinal disease as well as asthma, rheumatoid arthritis, inflammatory bowel disease and atherosclerosis.
Stephen Evans-Freke and Peter B Corr, co-founders and Managing General Partners of Celtic Therapeutics Holdings, said: "We look forward to a close and successful alliance with Resolvyx to optimize the medical potential and financial returns from this exciting class of novel anti-inflammatory molecules in the ophthalmology field. If approved, RX-10045 should provide superior efficacy to current therapeutic options in dry eye. We are eager to explore the activity of resolvins in additional ophthalmic indications as well."
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.